Nasdaq · Healthcare
NovoCure Ltd (NVCR)
As-reported financials and recent SEC filings for NovoCure Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$655.4M
Net income
$-136.2M
Net margin
-20.8%
Diluted EPS
$-1.22
ROE
-40.0%
P/E (TTM)
—
Market cap
$1.79B
Debt / equity
0.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M |
| Gross profit | $488.5M | $468.0M | $381.1M | $423.0M | $420.2M |
| Operating income | $-153.8M | $-170.5M | $-232.9M | $-89.5M | $-44.3M |
| Net income | $-136.2M | $-168.6M | $-207.0M | $-92.5M | $-58.4M |
| Diluted EPS | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-18
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →8-K2026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Go deeper on NVCR
Search NovoCure Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.